NDA 021928 · Pf Prism Cv
Chantix
Varenicline Tartrate · Oral
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jun 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
May 10, 2006
Approved uses
15
Original approval plus efficacy supplements
Registered trials
336
68 Phase 3, 23 recruiting
FAERS reports
76,596
31,194 serious, 1,581 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 23, 2026.
CHANTIX is indicated for use as an aid to smoking-cessation treatment. CHANTIX is a nicotinic receptor partial agonist indicated for use as an aid to smoking-cessation treatment. ( 1 and 2.1 )
Mechanism: Varenicline binds with high affinity and selectivity at α4β2 neuronal nicotinic acetylcholine receptors. The efficacy of CHANTIX in smoking cessation is believed to be the result of varenicline's activity at α4β2 sub-type of the nicotinic receptor where its binding produces agonist activity, while simultaneously preventing nicotine binding to these receptors. Electrophysiology studies in vitro and neurochemical studies in vivo have shown that varenicline binds to α4β2 neuronal nicotinic acetylcholine receptors and stimulates receptor-mediated activity, but at a significantly lower level than...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 22, 2019 Supplement 48 · Efficacy · priority review LabelLetter
- Jun 1, 2018 Supplement 45 · Efficacy LabelLetter
- Jun 1, 2018 Supplement 46 · Efficacy LabelLetter
- Dec 16, 2016 Supplement 40 · Efficacy LabelLetterReview
- Aug 12, 2016 Supplement 39 · Efficacy LabelLetterReview
- Oct 15, 2014 Supplement 33 · Efficacy LabelLetter
- Oct 15, 2014 Supplement 34 · Efficacy LetterLabel
- Sep 19, 2014 Supplement 36 · Efficacy LabelReviewLetter
- Sep 19, 2014 Supplement 32 · Efficacy ReviewLabelLetter
- Feb 19, 2013 Supplement 30 · Efficacy LabelLetter
- Dec 11, 2012 Supplement 31 · Efficacy LabelLetter
- Jul 22, 2011 Supplement 19 · Efficacy LabelReviewLetter
- Jul 22, 2011 Supplement 21 · Efficacy LabelReviewLetter
- Jul 22, 2011 Supplement 20 · Efficacy LetterReviewLabel
- May 10, 2006 Original approval · Type 1 - New Molecular Entity · priority review NovelPediatric Clinical Pharmacology ReviewLetterLabel
2 products under this application
- CHANTIX · VARENICLINE TARTRATE EQ 0.5MG BASE · TABLET, ORAL · Prescription · TE AB
- CHANTIX · VARENICLINE TARTRATE EQ 1MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Varenicline" as an intervention, any sponsor and status, largest first.
- Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric DisordersPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01456936 · 8,144 participants · Start Nov 2011 · Primary completion Jan 2015
Drug: Placebo; varenicline tartrate and 2 more · For: Smoking Cessation
Sites: Mobile, Alabama; Phoenix, Arizona; Encino, California · 156 sites in all
- Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01574703 · 4,595 participants · Start May 2012 · Primary completion Jul 2015
Drug: placebo; varenicline tartrate and 2 more · For: Smoking Cessation
Sites: Mobile, Alabama; Encino, California; Escondido, California · 134 sites in all
- Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I TrialPivotal-lookingRecruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT04604509 · 2,010 participants (planned) · Start Aug 4, 2020 · Primary completion Dec 31, 2028
Drug: Bupropion Hydrochloride Controlled-release; Nicotine Replacement and 1 more · For: Cigarette Smoking-Related Carcinoma
Sites: Houston, Texas
- A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking CessationPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00143286 · 2,000 participants · Start Apr 2003
Drug: varenicline (CP-526,555) · For: Smoking Cessation
Sites: Santa Ana, California; West Palm Beach, Florida; Lexington, Kentucky · 24 sites in all
- Risk Reduction in Coronary Heart DiseasePivotal-lookingCompleted
Sorlandet Hospital HFGovernment (non-federal)
NCT00679237 · 1,600 participants · Start Sep 2007 · Primary completion Dec 2019
Drug: betablocker, diuretics, ACEI, ARB,; statins, ezetimibe and 2 more · For: Coronary Heart Disease
Sites: Arendal, Norway
- A Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through ReductionPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01370356 · 1,510 participants · Start Jul 2011 · Primary completion Jul 2013
Drug: Varenicline Tartrate; Placebo · For: Smoking Cessation
Sites: Encino, California; Newport Beach, California; Jacksonville, Florida · 65 sites in all
- UW Quitting Using Intensive Treatment Study (QUITS)Pivotal-lookingCompleted
University of Wisconsin, MadisonAcademic, hospital or other
NCT03176784 · 1,251 participants · Start Nov 11, 2017 · Primary completion Jul 9, 2020
Drug: Varenicline; Nicotine patch · For: Tobacco Dependence
Sites: Madison, Wisconsin; Milwaukee, Wisconsin
- Pharmacogenetics of Nicotine Addiction TreatmentPivotal-lookingCompleted
University of PennsylvaniaAcademic, hospital or other
NCT01314001 · 1,246 participants · Start Dec 2010 · Primary completion Dec 2013
Drug: Varenicline; Placebo and 1 more · For: Nicotine Addiction
Sites: Buffalo, New York; Philadelphia, Pennsylvania; Houston, Texas · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea13,951
- depression8,329
- abnormal dreams7,633
- anxiety5,827
- drug ineffective5,559
- insomnia5,430
- vomiting4,244
- headache4,035
- suicidal ideation4,000
- malaise3,952
- feeling abnormal3,940
- nightmare3,151
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 213 |
| 2007 | 3,076 |
| 2008 | 4,745 |
| 2009 | 1,550 |
| 2010 | 29,906 |
| 2011 | 6,391 |
| 2012 | 6,935 |
| 2013 | 3,307 |
| 2014 | 3,575 |
| 2015 | 2,251 |
| 2016 | 2,447 |
| 2017 | 2,396 |
| 2018 | 2,274 |
| 2019 | 2,535 |
| 2020 | 1,792 |
| 2021 | 1,180 |
| 2022 | 1,027 |
| 2023 | 312 |
| 2024 | 218 |
| 2025 | 249 |
| 2026 | 217 |
Recalls
7 FDA enforcement reports for this application.
Aug 13, 2021 · Class II · Ongoing
CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit
Aug 13, 2021 · Class II · Ongoing
CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit
Jun 9, 2021 · Class II · Ongoing
CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit
Jun 9, 2021 · Class II · Ongoing
CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDAs acceptable interim acceptable intake limit
Jun 9, 2021 · Class II · Ongoing
CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDAs acceptable interim acceptable intake limit
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Chantix (Varenicline Tartrate)
2024 spending
$10K
Beneficiaries
14
25 claims
Per beneficiary
$706
$8.13 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $298,651,751 |
| 2021 | $153,238,580 |
| 2022 | $750,396 |
| 2023 | $88,399 |
| 2024 | $9,885 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Varenicline for Youth Nicotine Vaping Cessation: A Randomized Clinical Trial.
Evins AE, Cather C, Reeder HT, et al. · JAMA 2025 · Clinical Trial, Phase IV, Randomized Controlled Trial
- Cytisine for smoking cessation: A systematic review and meta-analysis.
Ofori S, Lu C, Olasupo OO, et al. · Drug Alcohol Depend 2023 · Meta-Analysis, Systematic Review
- Alcohol use disorder severity moderates clinical response to varenicline.
Donato S, Green R, Ray LA · Alcohol Clin Exp Res 2021 · Clinical Trial, Phase II, Multicenter Study
- Interventions for quitting vaping.
Butler AR, Lindson N, Livingstone-Banks J, et al. · Cochrane Database Syst Rev 2025 · Meta-Analysis, Systematic Review
- Effect of Cytisine vs Varenicline on Smoking Cessation: A Randomized Clinical Trial.
Courtney RJ, McRobbie H, Tutka P, et al. · JAMA 2021 · Comparative Study, Equivalence Trial
- Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.
Anthenelli RM, Benowitz NL, West R, et al. · Lancet 2016 · Multicenter Study, Randomized Controlled Trial
Sponsor: Pf Prism Cv
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.